Comprehensive Insights on Amgen: Dividend and Recent Developments Before the Aug 22, 2025, Ex-Dividend Date
Generated by AI AgentAinvest Dividend Digest
Monday, Aug 18, 2025 7:03 pm ET1min read
AMGN--
Aime Summary
Aime SummaryAmgen (AMGN) has announced its upcoming dividend details. The company has set an ex-dividend date of Aug 22, 2025, with an announcement made on Aug 1, 2025. Dividends are scheduled to be paid on Sep 12, 2025, at a rate of $2.38 per share. This amount is notably higher than the average of the last ten dividends per share, which stands at $1.274. The previous dividend was also issued at $2.38 per share, with the distribution type being a cash dividend.
Recently, AmgenAMGN-- has been in the spotlight for several significant events. As of late, the company reported a remarkable earnings beat, with earnings per share reaching $6.02, surpassing the estimated $5.28. This was accompanied by a 9.4% increase in revenue, showcasing Amgen's robust financial performance. Additionally, Amgen recently secured a legal victory that overturned a $50.3 million patent infringement verdict against Lindis Biotech. This development has positively influenced investor sentiment, as analysts indicated a potential boost in Amgen's stock performance. Over the past week, Amgen's strategic acquisition of Horizon Therapeutics has also been a focal point, further solidifying its position in the biotechnology sector. This acquisition, valued at approximately $27.8 billion, is one of Amgen's largest and is expected to enhance its therapeutic offerings, including treatments for rare diseases.
Amgen's financial health remains a critical area of analysis. The company's operating margin stands at 0.289, highlighting its efficient profit generation from core operations. However, the quick ratio of 0.817 suggests that Amgen may face challenges in covering short-term obligations if they were to come due simultaneously. The debt-to-equity ratio is notably high at 10.833, indicating a significant reliance on debt financing. These financial indicators are crucial for investors assessing the company's long-term viability and market competitiveness.
In conclusion, investors should note that Aug 22, 2025, is the ex-dividend date, marking the last opportunity to purchase Amgen's stock and be eligible for this dividend distribution. Any acquisitions made post this date will not qualify for the current dividend payout.
Recently, AmgenAMGN-- has been in the spotlight for several significant events. As of late, the company reported a remarkable earnings beat, with earnings per share reaching $6.02, surpassing the estimated $5.28. This was accompanied by a 9.4% increase in revenue, showcasing Amgen's robust financial performance. Additionally, Amgen recently secured a legal victory that overturned a $50.3 million patent infringement verdict against Lindis Biotech. This development has positively influenced investor sentiment, as analysts indicated a potential boost in Amgen's stock performance. Over the past week, Amgen's strategic acquisition of Horizon Therapeutics has also been a focal point, further solidifying its position in the biotechnology sector. This acquisition, valued at approximately $27.8 billion, is one of Amgen's largest and is expected to enhance its therapeutic offerings, including treatments for rare diseases.
Amgen's financial health remains a critical area of analysis. The company's operating margin stands at 0.289, highlighting its efficient profit generation from core operations. However, the quick ratio of 0.817 suggests that Amgen may face challenges in covering short-term obligations if they were to come due simultaneously. The debt-to-equity ratio is notably high at 10.833, indicating a significant reliance on debt financing. These financial indicators are crucial for investors assessing the company's long-term viability and market competitiveness.
In conclusion, investors should note that Aug 22, 2025, is the ex-dividend date, marking the last opportunity to purchase Amgen's stock and be eligible for this dividend distribution. Any acquisitions made post this date will not qualify for the current dividend payout.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet